CJC-1295 No DAC + Ipamorelin
Pre-mixed research formulation combining two complementary growth hormone secretagogues operating through distinct, non-overlapping receptor mechanisms. CJC-1295 No DAC activates pituitary GHRHR; Ipamorelin activates the ghrelin receptor (GHSR-1a). The combination is studied for synergistic pulsatile GH release exceeding either agent alone in published research models.
Mechanism of Action
CJC-1295 No DAC (also designated Modified GRF(1-29)) is a truncated, stabilised analogue of endogenous GHRH (growth hormone releasing hormone). Native GHRH is a 44-amino-acid peptide; the 1-29 fragment retains full GHRH receptor (GHRHR) binding affinity, while four amino acid substitutions (at positions 2, 8, 15, and 27) confer resistance to dipeptidyl peptidase IV (DPP-IV) degradation, extending the active half-life relative to native GHRH(1-29). The “No DAC” designation indicates the absence of a Drug Affinity Complex maleimide-albumin binding moiety, preserving shorter and more physiologically pulsatile GH release characteristics.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a growth hormone releasing peptide (GHRP). It acts as a selective agonist at the ghrelin receptor (GHSR-1a), expressed on anterior pituitary somatotrophs and in hypothalamic arcuate nucleus neurons. Unlike earlier-generation GHRPs (GHRP-2, GHRP-6), ipamorelin is characterised by high GH selectivity with minimal stimulation of ACTH, cortisol, or prolactin — a property relevant to research designs where these confounding hormonal variables need to be controlled.
The GHRHR (activated by CJC-1295 No DAC) and GHSR-1a (activated by Ipamorelin) signal through distinct intracellular cascades: GHRHR couples to Gs/adenylyl cyclase/cAMP/PKA, while GHSR-1a couples primarily to Gq/PLC/IP3/Ca2+. The convergence of two independent signalling cascades on the same somatotroph GH secretion apparatus is the mechanistic basis for the synergistic GH release studied in combination research designs. CJC-1295 No DAC is studied as establishing an amplified GH secretory baseline; ipamorelin is studied as triggering acute GH pulses via the ghrelin receptor axis.
Key Research Findings
- GHRH + GHRP combinations have been shown to produce synergistic GH release in both in vitro pituitary cell studies and in vivo rodent models, with combined effects exceeding either agent alone — establishing the mechanistic rationale for the combination format. Bowers and colleagues, GHRH/GHRP synergy literature, Journal of Clinical Endocrinology & Metabolism, 1990s–2000s.
- Ipamorelin selectivity for GH secretion without significant ACTH or cortisol stimulation has been documented in animal studies, distinguishing it pharmacologically from GHRP-2 and GHRP-6. Raun et al., European Journal of Endocrinology, 1998.
- CJC-1295 without DAC retains GHRH receptor binding and biological activity while producing shorter, more physiologically pulsatile GH release patterns in research models, consistent with its intermediate half-life relative to DAC-conjugated forms. Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006 (CJC-1295 with DAC; reference for the DAC-conjugated comparison).
- The GHRH + GHRP combination has been studied in models of GH deficiency research and age-related GH decline, where restoration of pulsatile GH secretion patterns is studied as a primary endpoint. GH secretagogue research literature in GH-deficient and ageing models, 2000s–2010s.
- GH downstream effects investigated as endpoints in combination GH secretagogue research include IGF-1 signalling, nitrogen balance, lipid metabolism, and musculoskeletal anabolic signalling in preclinical animal models — pathways relevant to the tissue repair research classification. Growth hormone / IGF-1 axis downstream signalling literature, endocrinology reviews 2000s–2010s.
Citations last reviewed: 1 October 2026
As Supplied by BasedPeps
Researcher FAQ
What is CJC-1295 No DAC + Ipamorelin?
CJC-1295 No DAC + Ipamorelin is a pre-mixed research formulation combining two complementary growth hormone secretagogues. CJC-1295 No DAC (Modified GRF(1-29)) is a truncated GHRH analogue that activates pituitary GHRHR to stimulate GH release. Ipamorelin is a selective GHRP pentapeptide acting at the ghrelin receptor (GHSR-1a) to trigger GH release through a distinct, non-overlapping mechanism. The combination is studied for synergistic pulsatile GH secretion.
How do GHRH and GHRP work together in research models?
GHRH analogues (CJC-1295 No DAC) and GHRP compounds (Ipamorelin) act through completely distinct receptor systems — GHRHR and GHSR-1a respectively — signalling via different intracellular cascades (cAMP and Ca2+ respectively). Published in vitro pituitary cell studies and in vivo rodent models have demonstrated that GHRH and GHRP combinations produce synergistic GH release exceeding either agent alone, establishing the mechanistic basis for combination research designs.
What is DAC and why is No DAC preferred in some research designs?
DAC (Drug Affinity Complex) refers to a maleimide-albumin binding moiety that, when attached to a GHRH analogue, produces prolonged half-life by reversible albumin binding — resulting in sustained, non-pulsatile GH elevation. CJC-1295 No DAC lacks this modification and produces shorter, more physiologically pulsatile GH pulses in research models. Research designs studying pulsatile GH secretion patterns or seeking to minimise prolonged supraphysiological GH levels typically prefer the No DAC form.
How is this blend stored and reconstituted?
Supplied as pre-mixed lyophilised powder in a single vial, stored at −20 °C. Reconstitution with sterile bacteriostatic water, gently swirling until dissolved. Reconstituted solution stored at 2–8 °C and used within 28 days per experimental protocol. Avoid vigorous shaking.
Does BasedPeps provide purity documentation?
Yes. Every BasedPeps lot includes a third-party Certificate of Analysis documenting HPLC purity (≥99% per peptide) and mass spectrometric identity confirmation for each component. Certificates of Analysis are available per batch on request.
View BasedPeps CJC-1295 No DAC + Ipamorelin
Research-grade pre-mixed GH secretagogue blend. Third-party HPLC and mass spectrometry verification per lot. Certificate of Analysis available on request. Dispatched from Riga, Latvia within 24 hours.
View BasedPeps CJC-1295 No DAC + Ipamorelin →